You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Suboptimal molecular response

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Chronic Myelogenous Leukemia - Chronic Phase Trial in United States (Nilotinib)

Terminated
Has Results
  • Chronic Myelogenous Leukemia - Chronic Phase
  • Los Angeles, California
  • +10 more
Jul 26, 2021

Adult Diabetic Macular Edema and Suboptimal Response to

Not yet recruiting
  • Diabetic Macular Edema
    • (no location specified)
    Jul 31, 2023

    Gaucher Disease, Type 1 Trial in Jerusalem (Ambroxol)

    Active, not recruiting
    • Gaucher Disease, Type 1
    • Jerusalem, Israel
      Shaare Zedek Medical Center
    May 24, 2022

    Ovarian Stimulation, Human Chorionic Gonadotropin, Oocyte Donors Trial in Thessaloniki (Dual trigger (human chorionic

    Recruiting
    • Ovarian Stimulation
    • +2 more
    • Dual trigger (human chorionic gonadotropin plus GnRH-agonist)
    • GnRH-agonist only trigger
    • Thessaloniki, Greece
      Embryolab Fertility Clinic
    Nov 20, 2023

    Improving Ovarian Stimulation; Suboptimal Responders Trial in Alicante (time of administration of Corifollitropin Alfa)

    Completed
    • Improving Ovarian Stimulation; Suboptimal Responders
    • time of administration of Corifollitropin Alfa
    • Alicante, Spain
      Instituto Bernabeu
    Apr 5, 2022

    According to Molecular Identification at Diagnosis

    Not yet recruiting
    • Chronic Myeloid Leukemia
    • Next Generation Sequencing (DNA and RNA)
    • (no location specified)
    Oct 28, 2022

    Atopic Dermatitis Trial in San Francisco (Dupilumab)

    Recruiting
    • Atopic Dermatitis
    • San Francisco, California
      University of California, San Francisco
    May 4, 2023

    Myelofibrosis Trial in Houston (CK0804)

    Not yet recruiting
    • Myelofibrosis
    • Houston, Texas
      The University of Texas MD Anderson Cancer Center
    Jun 28, 2022

    Myelofibrosis, Primary Myelofibrosis, Post-PV MF Trial in Canton (TL-895, Ruxolitinib)

    Recruiting
    • Myelofibrosis
    • +3 more
    • Birmingham, Alabama
    • +13 more
    Jan 10, 2023

    Marginal Zone Lymphoma, Follicular Lymphoma Trial in Aurora (Ublituximab, Umbralisib)

    Suspended
    • Marginal Zone Lymphoma
    • Follicular Lymphoma
    • Aurora, Colorado
      University of Colorado Hospital
    Feb 22, 2022

    Primary Myelofibrosis, Secondary Myelofibrosis Trial in Greifswald, Halle (Saale) (Fedratinib Oral Capsule [Inrebic], Nivolumab)

    Recruiting
    • Primary Myelofibrosis
    • Secondary Myelofibrosis
    • Greifswald, Germany
    • +1 more
    Jun 15, 2022

    Crohn's Disease, Ulcerative Colitis Trial (Samples)

    Not yet recruiting
    • Crohn's Disease
    • Ulcerative Colitis
    • Samples
    • (no location specified)
    Feb 8, 2023

    Infertility,Female Trial in Changsha (rLH)

    Recruiting
    • Infertility,Female
    • Changsha, Hunan, China
    • +1 more
    Jan 10, 2022

    Athletic Performance, Muscle Fatigue, Oxidative Stress Trial in Olomouc (Hydrogen rich water, Placebo)

    Enrolling by invitation
    • Athletic Performance
    • +2 more
    • Hydrogen rich water
    • Placebo
    • Olomouc, Czechia
      Palacky University, Faculty of Physical Culture
    Apr 11, 2023

    Near Patient Molecular Testing in Sepsis

    Active, not recruiting
    • Sepsis
    • Systemic Inflammatory Response Syndrome
      • Los Angeles, California
      • +2 more
      Jul 19, 2022

      Treatment in FH-deficient RCC Patients

      Recruiting
      • FH-Deficient RCC
      • +2 more
      • Laboratory analysis of samples
      • Shanghai, Shanghai, China
        Ethics Committee of Shanghai Renji Hospital
      Sep 6, 2022

      Respiratory Viral Infections in Pediatric Transplant Recipients

      Recruiting
      • Hematopoietic Cell Transplant
      • +2 more
        • Little Rock, Arkansas
        • +4 more
        Jan 11, 2023

        CML Trial in Ciudad Autonoma de Buenos Aire (Discontinuing treatment with Tyrosine Kinase Inhibitor after enrolment)

        Recruiting
        • CML
        • Discontinuing treatment with Tyrosine Kinase Inhibitor after enrolment
        • Ciudad Autonoma de Buenos Aire, Ciudad Autonoma De Buenos Aires, Argentina
          FUNDALEU
        Jun 29, 2023

        Leukemia, Acute Lymphocytic Trial in Durham (Copanlisib)

        Recruiting
        • Leukemia, Acute Lymphocytic
        • Durham, North Carolina
          Duke Cancer Center
        Jun 28, 2022

        Response to Therapy and Breast Cancer Behavior

        Recruiting
        • Breast Cancer
        • biologic sample preservation procedure
        • +2 more
        • Chapel Hill, North Carolina
          Lineberger Comprehensive Cancer Center at University of North Ca
        Jun 8, 2022

        Seborrheic Dermatitis Trial in New York (Ruxolitinib 1.5% Cream)

        Recruiting
        • Seborrheic Dermatitis
        • Ruxolitinib 1.5% Cream
        • New York, New York
          Icahn School of Medicine at Mount Sinai
        Mar 15, 2023

        Effect of Pharmacogenetics on Imatinib Plasma Level and Response

        Active, not recruiting
        • Chronic Myeloid Leukemia
        • PCR
        • HPLC-UV
        • Assiut, Egypt
          South Egypt Cancer Institute
        Aug 6, 2022

        Response to First Line Treatment in Lichen Planus

        Enrolling by invitation
        • Lichen Planus, Oral
        • Lichen Planus of Vulva
        • No interventions were administered to the patients as a part of this study.
        • Aberdeen, Aberdeen, Scotland, United Kingdom
          University of Aberdeen
        Apr 8, 2022

        Head Neck Cancer Trial in Little Rock (Optical Spectroscopy)

        Not yet recruiting
        • Head and Neck Cancer
        • Optical Spectroscopy
        • Little Rock, Arkansas
          University of Arkansas for Medical Sciences
        Mar 14, 2022

        Genetic Change Trial in Zhengzhou (Gene evolution and molecular response under Bevacizumab treatment)

        Recruiting
        • Genetic Change
        • Gene evolution and molecular response under Bevacizumab treatment
        • Zhengzhou, Henan, China
          Henan Provincial People's Hospital
        Aug 21, 2022